Evidence map›Paper›PMID 24871547›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014

Memantine effects on verbal memory in fragile X-associated tremor/ataxia syndrome (FXTAS): a double-blind brain potential study.

Jin-Chen Yang, Yu-Qiong Niu, Christa Simon, Andreea L Seritan, Lawrence Chen, Andrea Schneider, Shayan T Moghaddam, Paul J Hagerman, Randi J Hagerman, John M Olichney

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 41 citations in OpenAlex.

  1. Open-Label Allopregnanolone Treatment of Men with Fragile X-Associated Tremor/Ataxia Syndrome.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017
    Trial
  2. Trial
  3. Review
  4. Premutation Females with preFXTAS.International journal of molecular sciences · 2025
    Article
  5. Review
  6. Review
  7. Fragile X Premutation: Medications, Therapy and Lifestyle Advice.Pharmacogenomics and personalized medicine · 2021
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Can a Neurosteroid Ameliorate Fragile X-Associated Tremor/Ataxia Syndrome?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017
    Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Fragile X-associated tremor/ataxia syndrome.Annals of the New York Academy of Sciences · 2015
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jin-Chen Yang1] Center for Mind and Brain, University of California Davis, Davis, CA, USA [2] Department of Neurology, University of California Davis, School of Medicine, Sacramento, CA, USA.
Yu-Qiong Niu1] Center for Mind and Brain, University of California Davis, Davis, CA, USA [2] Department of Neurology, University of California Davis, School of Medicine, Sacramento, CA, USA.
Christa Simon1] Center for Mind and Brain, University of California Davis, Davis, CA, USA [2] Department of Neurology, University of California Davis, School of Medicine, Sacramento, CA, USA.
Andreea L SeritanDepartment of Psychiatry and Behavioral Sciences, University of California Davis, School of Medicine, Sacramento, CA, USA.
Lawrence Chen1] Center for Mind and Brain, University of California Davis, Davis, CA, USA [2] Department of Psychology, University of California Davis, Davis, CA, USA.
Andrea Schneider1] Medical Investigations of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, School of Medicine, Sacramento, CA, USA [2] Department of Pediatrics, University of California Davis, School of Medicine, Sacramento, CA, USA.
Shayan T Moghaddam1] Center for Mind and Brain, University of California Davis, Davis, CA, USA [2] College of Biological Sciences, University of California Davis, Davis, CA, USA.
Paul J Hagerman1] Medical Investigations of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, School of Medicine, Sacramento, CA, USA [2] Department of Biochemistry and Molecular Medicine, University of California Davis, Davis, CA, USA.
Randi J Hagerman1] Medical Investigations of Neurodevelopmental Disorders (MIND) Institute, University of California Davis, School of Medicine, Sacramento, CA, USA [2] Department of Pediatrics, University of California Davis, School of Medicine, Sacramento, CA, USA.ORCID 0000000150298448
John M Olichney1] Center for Mind and Brain, University of California Davis, Davis, CA, USA [2] Department of Neurology, University of California Davis, School of Medicine, Sacramento, CA, USA.
University of California, Davis · USUniversity of California Davis Medical Center · US

Funding

UC Davis Alzheimer's Disease Core CenterP30AG010129 · NIA · UNIVERSITY OF CALIFORNIA DAVIS · PI MEYER, OANH L · 1991 to 2020
$28.3M
GENOTYPE/PHENOTYPE RELATIONSHIPS IN FRAGILE X FAMILIESR01HD036071 · NICHD · UNIVERSITY OF CALIFORNIA DAVIS · PI PAUL J HAGERMAN, RANDI J. HAGERMAN · 1998 to 2026
$13.8M
Characterization and Treatment of CNS Abnormalities in Premutation Carriers (4 ofRL1AG032115 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAGERMAN, RANDI J. · 2007 to 2011
$5.8M
Trajectories and Markers of Neurodegeneration in Fragile X Premutation CarriersR01MH078041 · NIMH · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HESSL, DAVID R, RIVERA, SUSAN M · 2007 to 2017
$5.4M
Expression of the Fragile X GeneR01HD040661 · NICHD · UNIVERSITY OF CALIFORNIA DAVIS · PI HAGERMAN, PAUL J · 2002 to 2016
$4.3M
Development of targeted therapeutic agents for the treatment of FXTAS (2 of 6)RL1AG032119 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAGERMAN, PAUL J · 2007 to 2011
$4.1M
Neuro Therapeutics Research Institute (1 of 6)UL1DE019583 · NIDCR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAGERMAN, PAUL J · 2008 to 2011
$3.0M
Memory in Aging, Mild Cognitive impairment and ADR01AG018442 · NIA · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI OLICHNEY, JOHN M · 2001 to 2005
$1.3M
Electrophysiological Correlates of Cognitive Control in AutismK01MH087720 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI TAKARAE, YUKARI · 2010 to 2014
$645k
Multisensory Integration in Children with ASDR21MH086854 · NIMH · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SARON, CLIFFORD DARRYL · 2011 to 2012
$422k
FMR 1-SLS: Improving Fragile X diagnosis using amplification-free single locus taR42HD078988 · NICHD · PACIFIC BIOSCIENCES OF CALIFORNIA, INC. · PI TURNER, STEPHEN WHITFIELD · 2013 to 2013
$149k
Healthy Climate, Happy StudentsU79SM060482 · SU · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SERITAN, ANDREEA · 2012 to 2014
–
CMHS SAMHSA HHS 1U79SM060482-01NIA NIH HHS P30 AG010129NIA NIH HHS P30AG10129NIA NIH HHS R01 AG018442NIA NIH HHS R01AG018442NIA NIH HHS RL1 AG032115NIA NIH HHS RL1AG032115NIA NIH HHS RL1 AG032119NIA NIH HHS RL1AG032119NICHD NIH HHS HD036071NICHD NIH HHS R01HD036071NICHD NIH HHS R01 HD040661NICHD NIH HHS R42 HD078988NIDCR NIH HHS UL1 DE019583NIMH NIH HHS MH078041NIMH NIH HHS MH086854-01A1NIMH NIH HHS MH087720-02NIMH NIH HHS R01MH078041NIMH NIH HHS R01MH078041-04S1OCPHP CDC HHS PR101054PHS HHS MC22641
6 · The paper itself

Abstract

Older FMR1 premutation carriers may develop fragile X-associated tremor/ataxia syndrome (FXTAS), a neurodegenerative disorder manifesting cognitive deficits that often subsequently progress to dementia. To date, there is no specific treatment available for FXTAS. Studies have demonstrated the premutation-associated overactivation of glutamatergic receptors in neurons. Memantine, a NMDA receptor antagonist approved for treatment of Alzheimer's disease, thus was tested in the first placebo-controlled, double-blind, randomized clinical trial in FXTAS. Prior event-related brain potential (ERP) studies in FXTAS found reduced N400 repetition effect, a glutamate-related electrophysiological marker of semantic priming, and verbal memory processes. This substudy of the randomized clinical trial of memantine in FXTAS sought to use the N400 repetition effect to evaluate effects of chronic memantine treatment on verbal memory. Subsequent recall and recognition memory tests for the experimental stimuli were administered to characterize verbal memory. Data from 41 patients who completed the 1-year memantine trial (21 on memantine) and also completed longitudinal ERP studies were analyzed. Results showed treatment-associated benefits on both cued-recall memory and N400 repetition effect amplitude. Importantly, improvement in cued recall was positively correlated with amplitude increase of the N400 repetition effect. The placebo group, in contrast, displayed a significant reduction of the N400 repetition effect after 1 year. These results suggest that memantine treatment may have beneficial effects on verbal memory in FXTAS. Additional studies of memantine, perhaps in combination with other therapeutic agents, appear warranted, as symptomatic treatments and neuroprotective treatments are both needed for this recently recognized neurodegenerative disorder.

Indexed as

AtaxiaBrainDouble-Blind MethodElectroencephalographyEvoked PotentialsExcitatory Amino Acid AntagonistsFemaleFragile X SyndromeHumansLongitudinal StudiesMaleMemantineMemoryMiddle AgedNeuropsychological TestsNootropic AgentsExcitatory Amino Acid AntagonistsMemantineNootropic AgentsReceptors, N-Methyl-D-Aspartate

Identifiers

PMID24871547
PMCPMC4200486
OpenAlexW1987101796

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.